About this trial
The primary aim: is to compare the effect of US guided ESP block at two levels versus intracavitary blockade in medical thoracoscopy on total peri-procedural (intraoperative and post-operative 12 hours) nalbuphine consumption (mg) during medical thoracoscopy. Secondary aims: Time to first rescue analgesia, postoperative VAS, haemodynamics, recovery time (Aldert \> 9), and adverse events
Eligibility criteria
Qualifiers
100 patients belonging to American Society of Anesthesiologists (ASA) I-III scheduled for medical thoracoscopy under adequate sedation and analgesia.
Disqualifiers
Patients will be excluded if; history of allergy or contraindication to any of the studied drugs, BMI more than 35 kg/m2 chronic opioid use or abuse, patients for whom ESPB block is contraindicated (patient refusal, coagulation disorder, skin infection at the injection site), history of post-thoracotomy, chest wall deformity, severe uncontrolled comorbidity, intubated patients, or if the interventional physician wants general anaesthesia from the start
Trial design
Treatments tested in this trial
- ultrasound-guided erector spinae plane block in medical pleuroscopy
- Intracavitary anaesthesia ICA